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Abstract
Objective—Assess the feasibility of using serial bronchoalveolar lavage fluids (BALF) to
characterize the course of cell damage and inflammation in airways of pediatric patients with
acute burn or inhalation injury.
Design—Prospective, longitudinal descriptive pilot study.
Setting—Burn and Pediatric Intensive Care Units in a tertiary-care medical center.
Subjects—Six consecutive intubated, mechanically ventilated pediatric patients with acute
inhalational injuries were studied.
Interventions—Serial BALF specimens from clinically-indicated bronchoscopies were used to
measure DNA and cytokine levels.
Measurements and Main Results—BALF DNA levels for the 6 pediatric burn subjects were
highest within the first 72 hours after burn injury and declined thereafter. At the early stages after
injury, BALF DNA levels (median [min, max] 3789 [1170,11917] ng/ml) were similar to those in
adult burn patients and pediatric cystic fibrosis or bronchiectasis patients, and higher than those in
pediatric recurrent pneumonia patients. BALF DNA levels in children and adults with inhalation
injury correlated significantly with BALF IL-6, IL-8, and TGF-β1 levels. The patient with the
most severe early visible airway mucosal damage and soot pattern at bronchoscopy, as well as the
most extensive burns, also had the highest average early BALF DNA level (11917ng/ml) and the
longest ventilator course and hospital stay. Procedures were well tolerated.
Conclusions—In children with acute burn and inhalational injury, airway cellular damage and
inflammation (reflected in high BALF DNA levels) appear to peak during the first 72 hours after
burns or inhalation injury followed by a slow decline. Serial analysis of factors in airway
secretions is feasible and has the potential to reveal important pathophyisiologic pathways and
therapeutic targets for treatment of acute inhalational injuries.
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In burn victims, inhalation injury remains a significant risk factor for mortality and
respiratory morbidity, including airway obstruction and acute lung injury or acute
respiratory distress syndrome (ALI/ARDS). The mechanisms by which inhalation injury
contributes to this risk are unclear. One hypothesis is that a massive influx of inflammatory
mediators and cells (primarily DNA-rich neutrophils) results in direct injury to the airway,
leading to production of secretions and airway obstruction with mucus and products of
inflammatory cell breakdown including DNA [1]. Some existing therapies such as anti-
inflammatory agents or DNAse might be rational in this setting [2]. These agents are often
used in clinical practice but there are few data specifically supporting a pathophysiologic
rationale for their use [2–4].
Serial bronchoscopy is employed at some burn care centers for assessment of the extent of
inhalational injury, and for therapeutic purposes to clear soot and cellular debris from
airways [5, 6]. The latter may be especially important in children with inhalation injuries,
since their small airway caliber may make them more susceptible to airway obstruction [7].
Studies have demonstrated the importance of inflammatory cells and their breakdown
products in the pathophysiology of cystic fibrosis (CF), in which DNA from necrotic
neutrophils contributes to the viscosity of airway secretions that obstruct airways [8, 9].
There is evidence that the use of anti-inflammatory drugs or inhaled DNAse improves
morbidity in CF [2, 3, 10, 11]. Inhaled DNAse has also been studied in mechanically
ventilated pediatric patients with atelectasis and has been shown to decrease inflammation
and improve atelectasis compared to mechanical ventilation maneuvers alone [4, 12].
However, the composition of airway secretions in children with inhalation injury has not
been described.
We carried out a pilot study investigating inflammatory and injury markers in airway
secretions after burn injury, using serial bronchoalveolar lavage fluids (BALF) from
pediatric patients undergoing endotracheal intubation and bronchoscopies as part of their
care after burn injuries. Our general goal was to assess the feasibility of quantifying serial
markers of injury or inflammation in the setting of acute inhalational injuries in children.
Our specific goals were (1) to measure the quantity of DNA in airway secretions as a marker
of airway injury and inflammatory cell breakdown; (2) to compare DNA levels from
pediatric burn patients with those from relevant comparison populations; and (3) to assess
the relationship of BALF DNA levels to inflammatory factors and clinical parameters.
METHODS
Study Design and Patients
This was a single-center, prospective, descriptive study in which we measured levels of
DNA and inflammatory markers in BALF obtained during clinical care of pediatric patients
who were intubated after acute burn and inhalational injuries over a one-year period.
Patients underwent one or more diagnostic/therapeutic flexible bronchoscopic examinations
according to a standard protocol (see below) based on their clinical needs, as determined by
the attending physician at the University of North Carolina Hospitals/North Carolina Jaycee
Burn Center. A sample of consecutive pediatric patients admitted over a 1-year period was
planned. Excess BALF beyond that needed for clinical purposes was collected for the study
and processed as described below. Additionally, clinical data regarding outcomes and
severity (length of hospital and ICU stay, ventilator course duration, presence of infection,
% body surface area of burns (%BSA), and PaO2 to FiO2 ratios,-if available) were collected,
and digital images of the large airways were recorded for grading according to a previously
published semi-quantitative scale [13].
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We compared study samples to samples obtained from children with CF or bronchiectasis
undergoing diagnostic bronchoscopy for lower airway cultures; and children with chronic
cough or wheeze not due to bronchiectasis or CF who were undergoing diagnostic
bronchoscopy. Samples from these pediatric comparison groups were available from a
separate research study [14]. Finally, we obtained bronchial washing samples from a series
of intubated adult patients with similar burn/inhalational injuries as the children in the study.
The study was approved by the UNC Biomedical Institutional Review Board and informed
consent was obtained from all adult subjects or their legal representative and from the
parents of all pediatric subjects.
Bronchoscopy protocol
Flexible bronchoscopy and bronchoalveolar lavage were performed according to a protocol
developed jointly by the Burn Center and the UNC Children’s Airway Center. All patients
with suspected inhalation injury based on history and physical findings (e.g., prolonged
exposure to fire in an enclosed space or presence of carbonaceous debris around the nose
and/or mouth) underwent bronchoscopic evaluation within 24 hours after admission to
assess for the presence of inhalation injury. To perform the bronchoscopy, the bronchoscope
was inserted via the endotracheal tube, and the distal trachea and airways were inspected to
the level of the lobar bronchi. Bronchoalveolar lavage was carried out using standardized
lavage volumes as previously described [15]. The location of the initial lavage was in the
lobe which appeared to be most heavily involved with soot or mucosal damage, but lavages
were done in multiple locations. However, if no distinct “worst” location was apparent, then
the initial lavage was done in the right middle lobe or lingula. At subsequent procedures, the
same approach was taken, but BALF for research purposes was processed only for the lobe
identified as “worst” at the initial procedure for each individual patient. The frequency and
timing of subsequent procedures was at the discretion of the attending Burn Center
physician, and depended on several factors including the initial soot burden the severity of
initial mucosal damage and the degree of difficulty with mucus clearance.
In adult burn patients, a similar bronchoscopy protocol was used, but lavages were done in
both the left and right mainstem bronchi in all patients. At each procedure, an initial 20 ml
aliquot was instilled then suctioned back and collected for research purposes, with
subsequent aliquots at the discretion of the care team for therapeutic indications.
Bronchoalveolar lavages for clinical indications in pediatric comparison groups were done
as described above for pediatric burn patients, but on only a single occasion and typically in
only one lobe.
Video images of the airways recorded at bronchoscopy were scored according to the scale
described by Chou et al. in which central airways appearance is graded as G0 (negative), G1
(mild edema and hyperemia ± soot), G2 (severe edema and hyperemia ± soot), or G3
(ulcerations, necrosis, absence of bronchial secretions, dry) [13].
BALF processing
BALF specimens were processed within 24 hours of specimen collection. Previous studies
have suggested that BALF can be stored on ice for up to 24 hours without significant impact
on specimen viability[16] [15]. Briefly, total cell count was carried out and cytocentrifuged
BALF was stained with modified Wright stain for differential cell counts. The remaining
BALF was then centrifuged at 300 g and the resulting cell-free supernatant was stored at
−80° C for subsequent mediator measurements. BALF double-stranded DNA was quantified
using QuantIt™ PicoGreen® dsDNA Assay Kit (Invitrogen™ Ltd, Eugene, OR), a
fluorescent nucleic acid stain, according to the manufacturer’s instructions. BALF
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Interleukin-6 (IL-6), interleukin-8 (IL-8) and transforming growth factor β1 (TGF-β1)
assays were performed using commercial ELISA kits (R & D Systems, Minneapolis, MN)
according to the manufacturer’s instructions. These mediators were selected as
representative markers for inflammation and injury repair. [9, 17, 18]
Statistical methods
For descriptive purposes, data comparisons among multiple groups were done using
nonparametric 1-way ANOVA with Dunn’s post-test. Correlations between DNA and
cytokine levels in BALF were analyzed using linear regression and log transformed data. All
statistical comparisons were done using GraphPad Prism (GraphPad Prism Software, Inc.,
La Jolla, CA). P < 0.05 was considered statistically significant throughout.
RESULTS
Patient characteristics
Over the study period, we collected serial BALF from 6 children who required endotracheal
intubation after acute burn and inhalational injuries. All children were healthy prior to their
acute injury. Some of their clinical characteristics are shown in Table 1. Ages at the time of
injury ranged from 2–16 years. Three of the children were injured in house fires, two in
motor vehicle crashes, and one from a paint can explosion. All six children underwent an
initial bronchoscopy within the first 24 hours after injury. Subsequent bronchoscopies were
dictated by the initial severity of injury and subsequent clinical course, as per routine clinical
protocol. Percent body surface area (% BSA) burn in the 6 children ranged from 13%–50%.
The degree of initial visual evidence for inhalational injury varied from mild to severe. One
patient was transferred to another burn center at 6 days post injury and was lost to our
follow-up. For the remaining 5 children, the length of stay in ICU ranged from 14–167 days,
while overall hospital stay ranged from 28–254 days. Subject 6, who had both the highest
initial bronchoscopic injury grade and the most extensive burns in this series, also had the
lowest minimum PaO2/FiO2 ratio and longest ventilator course and hospital stay (Table 1).
No complications were noted for any of the bronchoscopy procedures.
DNA and inflammatory markers in BALF
DNA quantity in BALF for these six patients generally showed the highest levels within the
first several days after burn injury, and declined thereafter (Fig. 1) except for Subject 6 who
had the most severe injury (Table 1). As shown in Figure 1, the number and timing of
bronchoscopies varied among patients according to clinical indication. Cairns et al. have
shown in animal models that cytokine responses at <3 days post burn injury differ from
those obtained at later time points [19]. For descriptive analysis we averaged “early” (<3
days) data for each subject, when more than one procedure was done during that time frame.
Figure 2 shows that ”early” BALF DNA levels from pediatric burn patients (median [min,
max] = 3789 [1170,11917] ng/ml) were significantly elevated compared to specimens
obtained from pediatric patients undergoing clinically indicated bronchoscopies for chronic
or recurrent wheeze or pneumonia (208 [191,586] ng/ml), and similar to levels obtained
from pediatric CF/bronchiectasis patients (7196 [537,22840] ng/ml) and adult burn patients
2483 [304,16820] ng/ml). DNA levels generally followed the pattern seen for other markers
of inflammation.
“Early” BALF showed a predominance of neutrophils (71 ± 10 % neutrophils, and 1.29 ±
0.68 × 106 neutrophils/ml). In a subset of 3 of the children with burns, and in serial
specimens from 11 adult burn patients, there were sufficient BALF samples remaining to
measure levels of several inflammatory cytokines. Figure 3 shows that IL-8, IL-6 and TGF-
β1 levels for the both adult and pediatric patients all correlated significantly with DNA in
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these samples,(IL-6: r2=0.416, p=0.007; IL-8: r2=0.742, p<0.001; TGF-β1: r2=0.65, p<0.001
for pediatric patients). The adult and pediatric data are shown together for descriptive
comparison.
DNA and clinical indicators
Clinical grading of inhalational injury is typically done at initial presentation. For the
purposes of our study, we assessed the relationship between BALF DNA levels and
bronchoscopic evidence for inhalational injury at all available time points, using a semi-
quantitative injury scale of bronchoscopic images as described in the Methods section. There
were a total of 16 days for which both video images and BALF DNA data were available
among the 6 pediatric patients. No grade G0 images were observed. Median BALF DNA
levels from procedures with grade G1 appearance (median [min, max] 2729 [266,8168] ng/
ml; N = 7) tended to be lower than those with grade G2 or G3 (4157 [757,29275] ng/ml; N =
9), but there was marked variability and the observed differences were not statistically
significant. Similar results were found when comparing DNA levels between
bronchoscopies where visible soot was present (4609 [390,29275] ng/ml; N = 9) vs. not
(2729 [266,4859] ng/ml; N = 7). Patient #6 was the only initial severe (G3) classification in
this series, and also had the highest individual BALF DNA level (29,275 ng/ml on Day 1
post injury), greatest percent body surface area burn (50%), and the longest ICU and
hospital length of stay in the series (see Figure 4). Interestingly, a second increase in dsDNA
appeared to occur following a diagnosis of pneumonia in this patient.
DISCUSSION
In a small series of pediatric burn patients, we have described time courses for levels of total
DNA and inflammatory factors in lower respiratory secretions, and their relationships with
clinical factors. Our study suggests that studies of airway secretions in the setting of acute
inhalational injuries in children are feasible, since bronchoscopy and bronchoalveolar lavage
were well tolerated and several biomarkers of interest were easily measurable. Our finding
of markedly elevated “early” DNA levels in the child with the most severe inhalation injury
and clinical course, coupled with the overall correlation between DNA and inflammatory
cytokines, suggests that early bronchoscopy-derived markers of inflammation or injury
might predict clinical outcomes. This conclusion requires replication of our findings in
larger studies.
Our patients had variation in the extent of cutaneous burns. As has been well described in
other studies, cutaneous burns may havedistant organ effects (e.g., acute lung injury) that are
independent of inhalation injury [20, 21]. These effects may be responsible for a portion of
the inflammatory response seen in these subjects. A larger study could further elucidate this
relationship.
Our primary specific finding was that BALF DNA levels were elevated early after burn or
inhalation injury, and generally correlated with the cytokine markers of inflammation and
injury, IL-6, IL-8, and TGF-β1. While elevated early BALF levels of inflammatory
mediators IL-6 and IL-8 have been reported in a recent study of adult burn/inhalation
victims [22], we believe these are the first pediatric data describing airway responses to this
type of acute respiratory injury. Potential sources of DNA in airway secretions include
directly damaged epithelial cells and inflammatory cells responding to injury or infection [1,
9, 11]. For example, the second elevation of DNA in patient 6 following the diagnosis of
pneumonia-as might have been due to neutrophil responses to infection. Our data cannot
differentiate among these cellular sources, since all of the factors measured could be derived
from multiple cell types.
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The DNA levels observed in this series were similar to those from a comparison group of
children with bronchiectasis (Fig. 2), and also similar to those reported in the literature for
children with CF [8, 9]. In CF, DNA from lysed neutrophils is the major source of viscosity
in airway secretions [8–10], and treatment with DNAse has shown some clinical benefit in
terms of improvement in airways obstruction [3, 11]. While the pathophysiology of CF and
inhalation injury are obviously different, our finding of BALF DNA levels in the “CF range”
suggests a rationale to use DNAse to reduce risk of airway obstruction early in the setting of
acute inhalational injury. Controlled trials are required to provide evidence that this is
clinically effective. Additionally, future studies may better allow for grading of the secretion
pattern and determination of clinical indications for mucolytics.
Our study relied on airway secretions obtained during bronchoscopies done as part of a
clinical protocol at our center. Bronchoscopy has been described as having diagnostic and
potentially therapeutic usefulness in the setting of acute burns and inhalational injury [5, 6,
23, 24], and two recent studies describe similar data to ours, from bronchoscopic lavage
specimens in an inhalational injury population [25, 26]. Our clinical experience suggests that
bronchoscopy and bronchoalveolar lavage are well-tolerated in mechanically ventilated
children after burn and inhalational injury. Though limited, our data suggest the possibility
that the bronchoscopic appearance of the airways (soot, edema, hyperemia, necrosis etc.)
may reflect the severity of mucosal injury or inflammation, and may further be reflected in
specific BALF mediator concentrations.
Clinical research in the setting of critical illness is inherently difficult, and additional
limitations are present when investigating critically ill children. While the management
strategy during the study period was fairly uniform, our series of patients was heterogeneous
regarding type and amount of specific toxins inhaled, patient size, and sample availability
based on clinical management decisions. Additionally, variable dilution of native airway
secretions could well affect our data, and estimating this dilution is problematic especially in
the setting of the rapidly changing mucosal permeability [27–29]. We attempted to minimize
some of these sources of variability by comparing same-lobe BALF in individual children
over time and adjusting BAL aliquots by patient size, but conclusions are limited by the
small sample size given these sources of data heterogeneity. Finally, while all samples were
processed within 24 hours there was some variability in the timing of the processing of
samples due to the unpredictable timing of patient presentation, which may have introduced
some variability in the results.
Children may have an elevated risk for respiratory complications from thermal and
inhalational injuries. The pathophysiology of responses to these injuries is not well
understood in this age group. Despite limitations, our data suggest that clinically derived
specimens such as those we describe may serve as a useful resource for research aiming to
translate concepts from experimental models to the clinical arena.
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BALF DNA over time post injury for 6 pediatric burn patients. “Day 0” is the day of injury.
Each line represents a separate patient (one G1 patient had a single sample obtained on Day
1). For reference, horizontal broken line at 500 ng/ml is near both the upper limit for the
pediatric recurrent pneumonia comparison group, and the lower limit for the pediatric CF
comparison groups in the study.
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BALF DNA levels in pediatric burn patients compared to several other patient groups. (A)
Averaged DNA levels in first 72 hours after injury in 6 children with burns (Ped Burn
Acute), vs. 5 children with chronic bronchiectasis (Ped Bronchiectasis), 11 adult burn
victims (Adult Burn Acute), and 5 pediatric patients with recurrent pneumonia but without
bronchiectasis (Ped Rec Pneumonia). * = P < .05 vs. pediatric recurrent pneumonia group.
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Relationship of BALF dsDNA to (A) IL-8, (B) IL-6, and (C) TGF-β. Data are shown for
BALF samples from pediatric patients (in red) and adult patients (in black). Correlation
coefficients (r2) and P values calculated by linear regression for the samples from pediatric
patients are described in the text.
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Serial bronchoscopic images of the distal trachea in patient #6 (grade G3 inhalational injury
initially), demonstrating early soot and mucosal damage followed by clearing.
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